Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Inversago Pharma logo — Pioneering innovative therapies to enhance the lives of pati...

Inversago Pharma

Pioneering innovative therapies to enhance the lives of patients with metabolic and fibrotic conditions.

Founded 2015 Series C Total: $137.00M Biopharma, Biotechnology +2

General Information

Company Name Inversago Pharma
Founded Year 2015
Founders / Decision Makers
Team member Team member
Industries Biopharma, Biotechnology, Health Care +1
Funding Stage Series C
Social

BounceWatch is an independent company data service, not affiliated with Inversago Pharma. To contact Inversago Pharma, visit inversago.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Inversago Pharma compare?

A PDF of Inversago Pharma and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Inversago Pharma soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Inversago Pharma

Inversago Pharma is a Montreal-based biotech company, founded in 2015, that focuses on developing innovative therapies for patients with metabolic and fibrotic conditions. Specializing in CB1 blockade through peripherally-acting, CB1 inverse agonists, the company aims to enhance treatment options for a range of conditions including Diabetic Kidney Disease (DKD), Diabetic Nephropathy (DN), Type 1 and Type 2 Diabetes (T1D/T2D), Non-Alcoholic Steatohepatitis (NASH), obesity-related complications, hypertriglyceridemia (HTG), and fibrotic conditions such as Progressive Fibrosis - Interstitial Lung Disease (PF-ILD) and Idiopathic Pulmonary Fibrosis (IPF). Inversago Pharma recently received a $95.00M Series C investment on 17 October 2022 from notable investors including New Enterprise Associates, Amgen Ventures, T1D Fund, Forbion, adMare BioInnovations, Amorchem, Genesys Capital Management Inc, Fonds de solidarité FTQ. With a focus on pioneering therapies, the company aims to significantly impact the lives of patients in need of new treatment options for complex medical conditions.

Business keywords: biotech company, clinical-stage, therapies, metabolic conditions, fibrotic conditions, CB1 blockade, inverse agonists, Diabetic Kidney Disease, Diabetic Nephropathy, Type 1 Diabetes, Type 2 Diabetes, Non-Alcoholic Steatohepatitis, obesity-related complications, hypertriglyceridemia, Progressive Fibrosis

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series C $95.00M 8
New Enterprise Associates Amgen Ventures T1D Fund
New Enterprise Associates, Amgen Ventures +6
17 Oct 2022
Series B $35.00M 2
AQC Capital
AQC Capital, Fonds de solidarité FTQ
08 Sep 2020
Series A $7.00M -
25 Jul 2018

Inversago Pharma Alternatives & Competitors

View All Alternatives
Inversago Pharma vs
Cirius Therapeutics
Cirius Therapeutics

Pioneering the future of liver and metabolic disease treatment with innovative insulin sensitizers.

Series A
Biopharma, Biotechnology
Inversago Pharma vs
Promedior
Promedior

Pioneering advanced therapies to heal fibrotic and inflammatory diseases at their source, enhancing...

Venture round
Biopharma, Biotechnology
Inversago Pharma vs
Madrigal Pharmaceuticals
Madrigal Pharmaceuticals United States

Madrigal is focused on delivering novel therapeutics for MASH, a serious liver disease.

IPO
1129 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Inversago Pharma

Pioneering innovative therapies to enhance the lives of patients with metabolic and fibrotic conditions.
Inversago Pharma was founded in 2015.
Inversago Pharma operates in Biopharma, Biotechnology, Health Care and Pharmaceutical. Its work centres on biotech company, clinical-stage, therapies and metabolic conditions.
Inversago Pharma has completed 3 funding rounds, raising a total of $137.00M. The latest funding stage is Series C.
Top alternatives and competitors to Inversago Pharma include Cirius Therapeutics, Promedior, Madrigal Pharmaceuticals, OrsoBio. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Inversago Pharma and Cirius Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Inversago Pharma, https://bouncewatch.com/company/inversago-pharma, updated 26 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes